GlassScriptPhysician profile
Stacy Schoenbach
NPI 1073037032
$3,854.77
in general payments reported to CMS, 2019-2025
13 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.38 · 2022: $132 · 2023: $1,158 · 2024: $1,085 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $714.66 | 2023-2025 | Auvelity |
| Abbvie INC. | $685.46 | 2023-2025 | |
| Alkermes, INC. | $677.45 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $489.28 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.81 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $248.46 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $126.34 | 2025 | Spravato |
| Tris Pharma INC | $124.99 | 2023 | Dyanavel Xr, Quillichew Er, Quillivant |
| Supernus Pharmaceuticals, INC. | $118.62 | 2025 | Qelbree |
| Neurocrine Biosciences, INC. | $118.09 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $111.94 | 2025 | Fanapt |
| Neos Therapeutics, LP | $31.38 | 2021 | |
| Eisai INC. | $20.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Schoenbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.